Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Progesterone Antibody (B14)

Catalog #:   RGK61502 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a
Applications: ELISA, SPR
Accession: ChEBI: 17026
Overview

Catalog No.

RGK61502

Species reactivity

General

Host species

Mouse

Isotype

IgG2a

Clonality

Monoclonal

Target

Progesterone, Agolutin, 17α-progesterone, Corpus luteum hormone, CAS: 57-83-0

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

ChEBI: 17026

Applications

ELISA, SPR

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

B14

Data Image
References

Effects of sexual dimorphism and estrous cycle on murine Clostridioides difficile infection., PMID:40475524

Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study., PMID:40405072

Female breast cancer classification using immunohistochemistry biomarkers staining in Botswana., PMID:40389885

Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study., PMID:40339592

Interference of recombinant human interferon α2b in human chorionic gonadotropin assays: a case report and clinical analysis., PMID:40330929

A Rare Case of Uterine-Origin Vulvar Leiomyoma Occurring in a Juvenile Girl: Case Report and Literature Review., PMID:40322727

Beyond antibodies: Beta-2 glycoprotein I as the unsung guardian of pregnancy., PMID:40279303

Incidence, Clinicopathologic Features, and Follow-Up Results of human epidermal growth factor receptor-2-Ultralow Breast Carcinoma., PMID:40274067

Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147 Antibody., PMID:40265417

TRIM22 governs tumorigenesis and protects against endometrial cancer-associated cachexia by inhibiting inflammatory response and adipose thermogenic activity., PMID:40200303

Novel Estrogen Receptor - Targeted Therapies in Hormone-Receptor Positive Breast Cancer., PMID:40163189

FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma., PMID:40150910

Distinguishing Low Expression Levels of Human Epidermal Growth Factor Receptor 2 in Breast Cancer: Insights from Qualitative and Quantitative Magnetic Resonance Imaging Analysis., PMID:40137571

Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review., PMID:40124876

Prognostic value of progesterone receptor expression in non-small cell lung cancer tissue., PMID:40117033

Molecular Shape-Preserving Au Electrode for Progesterone Detection., PMID:40096471

Atypical Endometriosis - An Overview of the Issue and Personal Experiences., PMID:40088443

Detection of Estrogen Receptor Status in Breast Cancer Cytology Samples by an Optical Nanosensor., PMID:40083881

Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review., PMID:40076535

Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial., PMID:40049198

The proteomic landscape of trophoblasts unravels calcium-dependent syncytialization processes and beta-chorionic gonadotropin (ß-hCG) production., PMID:40038668

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy., PMID:40021215

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer., PMID:40010764

Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline., PMID:40002228

NUPR1 contributes to endocrine therapy resistance by modulating BIRC5 expression and inducing luminal B-ERBB2+ subtype-like characteristics in estrogen receptor-positive breast cancer cells., PMID:39991577

Clinicopathologic characterization of hormone-receptor positive, human epidermal growth factor receptor 2 Null, Ultralow, and Low breast carcinoma in the metastatic setting., PMID:39988059

HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN., PMID:39953511

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer., PMID:39917260

Multivalent Redox Reversible Conversion-Enhanced Electrochemiluminescence Strategy for Progesterone Detection., PMID:39908417

Effect of different colors and intensity of light emitting diode on the production performance, egg quality, hormonal profile and the economics of layers kept in environment control house., PMID:39903400

Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: What before chemotherapy? A glimpse into the future., PMID:39900320

Low progesterone levels and their role in the co-existence of polycystic ovary syndrome and rheumatoid arthritis: A comprehensive analysis among Iraqi patient., PMID:39870327

Sex hormones and allergies: exploring the gender differences in immune responses., PMID:39840271

RANK/RANKL Signaling Pathway in Breast Development and Cancer., PMID:39821032

Role of sex hormones in the reactivation of Toxocara canis larvae in pregnant bitches., PMID:39818124

Exploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization., PMID:39794852

Impact of the menstrual cycle phases and time of day on markers of stress: salivary α-amylase and secretory immunoglobulin A., PMID:39757714

The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis., PMID:39753653

Radiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective., PMID:39751821

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy., PMID:39744916

Sensitivity-enhanced competitive lateral flow immunoassays by polycaprolactone electrospun stacking pad: Estrous determination in whole blood., PMID:39731824

In silico selection against progesterone receptor DNA-binding domain., PMID:39719189

A fluorescent signal amplification strategy via host-guest recognition for cortisol detection., PMID:39709860

Tissue-resident natural killer cells derived from conventional natural killer cells are regulated by progesterone in the uterus., PMID:39708955

Postorgasmic illness syndrome benefiting from omalizumab and antidepressant: a case report., PMID:39707470

Advancements in clinical research and emerging therapies for triple-negative breast cancer treatment., PMID:39675457

Impact of Laboratory-Measured Euthyroid Hashimoto's Thyroiditis on Reproductive Hormone Profile in Women with Obesity., PMID:39655636

Membrane progesterone receptor e (paqr9) is necessary for chorion elevation in zebrafish., PMID:39643858

Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials., PMID:39640887

Clinical and prognostic effects of microvascular density and FOXP3 positive T cells in breast cancer., PMID:39639042

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Progesterone Antibody (B14) [RGK61502]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only